Reframe Daily: Fiber eases IBS-C; one-night seizure dose works; craving patch helps; stronger myopia drops; autism social gains

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A prebiotic fiber eased IBS-C symptoms; a single bedtime dose of levetiracetam controlled seizures in a common childhood epilepsy; a wearable heart-rate-training patch reduced drug and alcohol cravings; twice-daily low-dose atropine eye drops slowed fast myopia in children; and memantine improved social functioning in youths with autism.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: People with constipation-type IBS felt better and enjoyed life more after taking a daily prebiotic fiber mix. It’s safe, cheap, and you can buy it today.

A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation-predominant IBS

Market readiness: 😀😀😀😀😀 (on shelves now; positive RCT signal, easy to implement in routine care). 

Good news: A single night-time dose of levetiracetam controlled seizures as well as standard dosing for a common childhood epilepsy—while improving adherence and parent satisfaction.

Safety and efficacy of one-dose nocturnal levetiracetam for the treatment of self-limited epilepsy with centrotemporal spikes: a randomized clinical trial

Market readiness: 😀😀😀😀😀 (FDA-approved drug; study supports an immediately usable dosing schedule). 

Good news: A wearable-device heart-rate-variability biofeedback program cut cravings and substance use in adults in recovery, pointing to a practical, non-drug add-on to treatment.

Heart Rate Variability Biofeedback for Substance Use Disorder: A Randomized Clinical Trial

Market readiness: 😀😀😀😀 (devices already sold; phase 2 efficacy shown—needs larger phase 3 for guidelines). 

Good news: For kids with fast-worsening nearsightedness, 0.01% atropine eye drops twice daily slowed progression more than once-daily—without extra side effects.

Efficacy and safety of twice-daily administration of 0.01% atropine eye drops in children with fast-progressing myopia: a randomized controlled trial

Market readiness: 😀😀😀😀 (low-dose atropine is widely compounded in the US; regimen is adoptable now though not FDA-approved for myopia).

Good news: In youths with autism, memantine improved social functioning over placebo in a controlled trial—an encouraging step toward a new use for an existing medicine.

Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder: A Randomized Clinical Trial

Market readiness: 😀😀😀 (drug is on market for other uses; small RCT suggests promise but more/larger trials needed before routine use).  

Thank you for taking the time to take care of yourself and your loved ones.